BIII 890 CL
Sponsors
Boehringer Ingelheim
Conditions
HealthyStroke
Phase 1
Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL
TerminatedNCT02268136
Start: 1999-04-30Updated: 2014-10-20
Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers
CompletedNCT02269215
Start: 2000-01-31Updated: 2014-10-21